Switch theme
Sign up to access all valuation multiples
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
1897
18.5K+
LTM Revenue $8.4B
LTM EBITDA $2.4B
$53.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lonza Group has a last 12-month revenue (LTM) of $8.4B and a last 12-month EBITDA of $2.4B.
In the most recent fiscal year, Lonza Group achieved revenue of $7.9B and an EBITDA of $1.9B.
Lonza Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lonza Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.4B | XXX | $7.9B | XXX | XXX | XXX |
| Gross Profit | $2.9B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $2.4B | XXX | $1.9B | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $1.6B | XXX | $1.1B | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $972M | XXX | $764M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lonza Group's stock price is CHF 569 (or $683).
Lonza Group has current market cap of CHF 41.1B (or $49.3B), and EV of CHF 44.5B (or $53.4B).
See Lonza Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.4B | $49.3B | XXX | XXX | XXX | XXX | $18.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lonza Group has market cap of $49.3B and EV of $53.4B.
Lonza Group's trades at 6.8x EV/Revenue multiple, and 28.8x EV/EBITDA.
Equity research analysts estimate Lonza Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lonza Group has a P/E ratio of 50.7x.
See valuation multiples for Lonza Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $49.3B | XXX | $49.3B | XXX | XXX | XXX |
| EV (current) | $53.4B | XXX | $53.4B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 22.3x | XXX | 28.8x | XXX | XXX | XXX |
| EV/EBIT | 33.5x | XXX | 49.0x | XXX | XXX | XXX |
| EV/Gross Profit | 18.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 50.7x | XXX | 64.6x | XXX | XXX | XXX |
| EV/FCF | -1306.3x | XXX | -311.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLonza Group's last 12 month revenue growth is 14%
Lonza Group's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Lonza Group's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lonza Group's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lonza Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lonza Group acquired XXX companies to date.
Last acquisition by Lonza Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Lonza Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lonza Group founded? | Lonza Group was founded in 1897. |
| Where is Lonza Group headquartered? | Lonza Group is headquartered in Switzerland. |
| How many employees does Lonza Group have? | As of today, Lonza Group has 18.5K+ employees. |
| Who is the CEO of Lonza Group? | Lonza Group's CEO is Mr. Albert M. Baehny. |
| Is Lonza Group publicy listed? | Yes, Lonza Group is a public company listed on SWX. |
| What is the stock symbol of Lonza Group? | Lonza Group trades under LONN ticker. |
| When did Lonza Group go public? | Lonza Group went public in 2002. |
| Who are competitors of Lonza Group? | Similar companies to Lonza Group include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Lonza Group? | Lonza Group's current market cap is $49.3B |
| What is the current revenue of Lonza Group? | Lonza Group's last 12 months revenue is $8.4B. |
| What is the current revenue growth of Lonza Group? | Lonza Group revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Lonza Group? | Current revenue multiple of Lonza Group is 6.3x. |
| Is Lonza Group profitable? | Yes, Lonza Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lonza Group? | Lonza Group's last 12 months EBITDA is $2.4B. |
| What is Lonza Group's EBITDA margin? | Lonza Group's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Lonza Group? | Current EBITDA multiple of Lonza Group is 22.3x. |
| What is the current FCF of Lonza Group? | Lonza Group's last 12 months FCF is -$40.9M. |
| What is Lonza Group's FCF margin? | Lonza Group's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Lonza Group? | Current FCF multiple of Lonza Group is -1306.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
